Traws Pharma, Inc. (TRAW)
NASDAQ: TRAW · Real-Time Price · USD
1.420
+0.030 (2.16%)
At close: May 30, 2025, 4:00 PM
1.380
-0.040 (-2.82%)
After-hours: May 30, 2025, 6:33 PM EDT
Traws Pharma Employees
As of December 31, 2024, Traws Pharma had 7 total employees, including 6 full-time and 1 part-time employees. The number of employees decreased by 11 or -61.11% compared to the previous year.
Employees
7
Change (1Y)
-11
Growth (1Y)
-61.11%
Revenue / Employee
$32,429
Profits / Employee
-$4,944,000
Market Cap
7.90M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
TRAW News
- 3 days ago - Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness - GlobeNewsWire
- 15 days ago - Traws Pharma Reports First Quarter 2025 Results and Business Highlights - GlobeNewsWire
- 2 months ago - Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript - Seeking Alpha
- 2 months ago - Traws Pharma Announces Management Updates - GlobeNewsWire
- 2 months ago - Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET - GlobeNewsWire
- 2 months ago - Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR - GlobeNewsWire
- 2 months ago - Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR - GlobeNewsWire
- 3 months ago - Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil - GlobeNewsWire